Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01572636 · ClinicalTrials.gov registry record
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- 20
- Enrollment target
NCT01572636 is a clinical trial that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 20 participants.
The verdict
NCT01572636 was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation (HSCT) according to a University of Minnesota myeloablative HSCT protocol.
Interventions
- DRUG Laronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2018-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01572636
The ClinicalTrials.gov registry entry for NCT01572636 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Laronidase is the first listed.
NCT01572636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01572636 about?
NCT01572636 is a clinical study titled "Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome". This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation (HSCT) according to a University of Minnesota myeloablative HSCT protocol.
What is the current status of trial NCT01572636?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2012-03-28. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT01572636?
The interventions under investigation include: Laronidase (DRUG).
Who is sponsoring clinical trial NCT01572636?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.